EMA’s human medicines committee (CHMP) recommended 14 medicines for approval at its September 2025 meeting.
The committee recommended granting a marketing authorisation for Enflonsia (clesrovimab), a medicine indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants.
